Conference Coverage

DDW: VIDEO: What we don’t know in the management of liver disease and coagulopathy


 

AT DDW 2015

References

WASHINGTON – Your patient has cirrhosis, platelets 60,000 mm3, an INR of 2.0, serum creatinine of 1.2 mg/dL, and requires an endoscopic retrograde cholangiopancreatography with sphincterotomy.

What do you do next?

Management of a patient such as this is challenging, but not just because of the long-perceived risk for bleeding, Dr. Patrick S. Kamath of the Mayo Clinic in Rochester, Minn., said during a clinical symposium at the annual Digestive Disease Week.

Several other factors must be considered, including the clotting risk in patients with liver disease and the fact that procedure-related bleeding risk cannot be adequately determined preprocedure. Transfusions also carry their own dangers in this patient population and should be approached with caution, he said.

To hear more from this world-renowned liver expert, check out our interview as we sat down with Dr. Kamath at this year’s DDW.

Dr. Kamath reported no relevant financial conflicts.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

pwendling@frontlinemedcom.com

On Twitter @pwendl

Recommended Reading

More children surviving cancer, but they still face chronic conditions
MDedge Hematology and Oncology
Vaccine pioneer begins reign as acting director of the National Cancer Institute
MDedge Hematology and Oncology
AF patients receive unnecessary oral anticoagulants
MDedge Hematology and Oncology
No growth hormone/cancer link in kids without malignancy risks
MDedge Hematology and Oncology
Preliminary analysis confirms birth defect-cancer association
MDedge Hematology and Oncology
Encouraging outcomes continue following CAR T cell therapy in kids
MDedge Hematology and Oncology
Children with advanced cancer need greater palliative care
MDedge Hematology and Oncology
More than 75% with sickle cell crises don’t get hydroxyurea
MDedge Hematology and Oncology
Reserve thrombophilia testing for select subgroups
MDedge Hematology and Oncology
Augmenting therapy boosts event-free survival in high-risk Wilms tumor
MDedge Hematology and Oncology